P2RX7 and breast cancer: Based on the previous data, SIM can blunt the glycolysis potential in MDA-MB-231 cells, which exhibit higher glycolytic activity compared to the other BC cell lines, like MCF-7 produce their energy via mitochondrial activity.36 The changes in lipid content and synthesis are related to the reduced viability in cancer cells after treatment with SIM.37 The stimulation of purinergic receptor P2X7/Akt signaling axis is another tumoricidal property of the statin family.38